How many other drugs would they have which could simultaneously:
a) extend their patent life by up to 20 years,
b) expand their patient population to include people with a history of cardiac problems,
c) increase the effectiveness of Kyprolis, and,
d) result in less severe side-effects in patients receiving Kyprolis.
I would expect the list is not that long.
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-56
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 8662 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |